|
1
|
Alam MW, Boreas M, Lind DE,
Cervantes-Madrid D, Umapathy G, Palmer RH and Hallberg B:
Alectinib, an anaplastic lymphoma kinase inhibitor, abolishes ALK
activity and growth in alk-positive neuroblastoma cells. Front
Oncol. 9:5792019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Calvo C, Storey C, Morcrette G, Akl P,
Freneaux P, Pierron G, Trang H, Aerts I, Schleiermacher G,
Philippe-Chomette P, et al: Metastatic neuroblastoma in a patient
with ROHHAD: A new alert regarding the risk of aggressive
malignancies in this rare condition. Pediatr Blood Cancer.
66:e279062019.PubMed/NCBI
|
|
3
|
Garcia M, Rodriguez-Hernandez CJ,
Mateo-Lozano S, Perez-Jaume S, Goncalves-Alves E, Lavarino C, Mora
J and de Torres C: Parathyroid hormone-like hormone plays a dual
role in neuroblastoma depending on PTH1R expression. Mol Oncol.
13:1959–1975. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Grasso S, Cangelosi D, Chapelle J, Alzona
M, Centonze G, Lamolinara A, Salemme V, Angelini C, Morellato A,
Saglietto A, et al: The SRCIN1/p140Cap adaptor protein negatively
regulates the aggressiveness of neuroblastoma. Cell Death Differ.
27:790–807. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bhoopathi P, Pradhan AK, Bacolod MD, Emdad
L, Sarkar D, Das SK and Fisher PB: Regulation of neuroblastoma
migration, invasion, and in vivo metastasis by genetic and
pharmacological manipulation of MDA-9/syntenin. Oncogene.
38:6781–6793. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pacenta HL and Macy ME: Entrectinib and
other ALK/TRK inhibitors for the treatment of neuroblastoma. Drug
Des Devel Ther. 12:3549–3561. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Campbell K, Shyr D, Bagatell R, Fischer M,
Nakagawara A, Nieto AC, Brodeur GM, Matthay KK, London WB and
DuBois SG: Comprehensive evaluation of context dependence of the
prognostic impact of MYCN amplification in neuroblastoma: A report
from the International Neuroblastoma Risk Group (INRG) project.
Pediatr Blood Cancer. 66:e278192019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yu Y, Chen F, Yang Y, Jin Y, Shi J, Han S,
Chu P, Lu J, Tai J, Wang S, et al: lncRNA SNHG16 is associated with
proliferation and poor prognosis of pediatric neuroblastoma. Int J
Oncol. 55:93–102. 2019.PubMed/NCBI
|
|
9
|
Avitabile M, Lasorsa VA, Cantalupo S,
Cardinale A, Cimmino F, Montella A, Capasso D, Haupt R, Amoroso L,
Garaventa A, et al: Association of PARP1 polymorphisms with
response to chemotherapy in patients with high-risk neuroblastoma.
J Cell Mol Med. 24:4072–4081. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ye M, Ma J, Liu B, Liu X, Ma D and Dong K:
Linc01105 acts as an oncogene in the development of neuroblastoma.
Oncol Rep. 2019.(Epub ahead of print). View Article : Google Scholar
|
|
11
|
Liu Z, Yang L, Zhong C and Zhou L: EZH2
regulates H2B phosphorylation and elevates colon cancer cell
autophagy. J Cell Physiol. 235:1494–1503. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kosalai ST, Morsy M, Papakonstantinou N,
Mansouri L, Stavroyianni N, Kanduri C, Stamatopoulos K, Rosenquist
R and Kanduri M: EZH2 upregulates the PI3K/AKT pathway through
IGF1R and MYC in clinically aggressive chronic lymphocytic
leukaemia. Epigeneticst. 14:1125–1140. 2019. View Article : Google Scholar
|
|
13
|
Pediconi N, Salerno D, Lupacchini L,
Angrisani A, Peruzzi G, De Smaele E, Levrero M and Belloni L: EZH2,
JMJD3, and UTX epigenetically regulate hepatic plasticity inducing
retro-differentiation and proliferation of liver cells. Cell Death
Dis. 10:5182019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim KH and Roberts CW: Targeting EZH2 in
cancer. Nat Med. 22:128–134. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yan KS, Lin CY, Liao TW, Peng CM, Lee SC,
Liu YJ, Chan WP and Chou RH: EZH2 in cancer progression and
potential application in cancer therapy: A friend or foe? Int J Mol
Sci. 18:11722017. View Article : Google Scholar
|
|
16
|
Ma J, Zhang J, Weng YC and Wang JC:
EZH2-mediated microRNA-139-5p regulates epithelial-mesenchymal
transition and lymph node metastasis of pancreatic cancer. Mol
Cells. 41:868–880. 2018.PubMed/NCBI
|
|
17
|
Liu Q, Wang G, Li Q, Jiang W, Kim JS, Wang
R, Zhu S, Wang X, Yan L, Yi Y, et al: Polycomb group proteins EZH2
and EED directly regulate androgen receptor in advanced prostate
cancer. Int J Cancer. 145:415–426. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang C, Liu Z, Woo CW, Li Z, Wang L, Wei
JS, Marquez VE, Bates SE, Jin Q, Khan J, et al: EZH2 mediates
epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU,
RUNX3, and NGFR. Cancer Res. 72:315–324. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Delas MJ, Jackson BT, Kovacevic T,
Vangelisti S, Munera ME, Wild SA, Stork EM, Erard N, Knott S and
Hannon GJ: lncRNA spehd regulates hematopoietic stem and progenitor
cells and is required for multilineage differentiation. Cell Rep.
27:719–729.e6. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhong Y, Wang J, Lv W, Xu J, Mei S and
Shan A: lncRNA TTN-AS1 drives invasion and migration of lung
adenocarcinoma cells via modulation of miR-4677-3p/ZEB1 axis. J
Cell Biochem. 120:17131–17141. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cairns J, Ingle JN, Kalari KR, Shepherd
LE, Kubo M, Goetz MP, Weinshilboum RM and Wang L: The lncRNA
MIR2052HG regulates ERalpha levels and aromatase inhibitor
resistance through LMTK3 by recruiting EGR1. Breast Cancer Res.
21:472019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Schmidt K, Carroll JS, Yee E, Thomas DD,
Wert-Lamas L, Neier SC, Sheynkman G, Ritz J and Novina CD: The
lncRNA SLNCR recruits the androgen receptor to EGR1-bound genes in
melanoma and inhibits expression of tumor suppressor p21. Cell Rep.
27:2493–2507.e4. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jin L, Cai Q, Wang S, Wang S, Mondal T,
Wang J and Quan Z: Long noncoding RNA MEG3 regulates LATS2 by
promoting the ubiquitination of EZH2 and inhibits proliferation and
invasion in gallbladder cancer. Cell Death Dis. 9:10172018.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang Y, Xie Y, Li L, He Y, Zheng D, Yu P,
Yu L, Tang L, Wang Y and Wang Z: EZH2 RIP-seq identifies
tissue-specific long non-coding RNAs. Curr Gene Ther. 18:275–285.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Su M, Xiao Y, Tang J, Wu J, Ma J, Tian B,
Zhou Y, Wang H, Yang D, Liao QJ and Wang W: Role of lncRNA and EZH2
interaction/regulatory network in lung cancer. J Cancer.
9:4156–4165. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim B: Western blot techniques. Methods
Mol Biol. 1606:133–139. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gagliardi M and Matarazzo MR: RIP: RNA
immunoprecipitation. Methods Mol Biol. 1480:73–86. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xia W, Hu J, Ma J, Huang J, Jing T, Deng
L, Zhang J, Jiang N, Ma D and Ma Z: Mutations in TOP2B cause
autosomal-dominant hereditary hearing loss via inhibition of the
PI3K-Akt signalling pathway. Febs Lett. 593:2008–2018. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kong L, Tan L, Lv R, Shi Z, Xiong L, Wu F,
Rabidou K, Smith M, He C, Zhang L, et al: A primary role of TET
proteins in establishment and maintenance of De Novo bivalency at
CpG islands. Nucleic Acids Res. 44:8682–8692. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ozcelik D and Pezacki JP: Small molecule
inhibition of protein disulfide isomerase in neuroblastoma cells
induces oxidative stress response and apoptosis pathways. Acs Chem
Neurosci. 10:4068–4075. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen L, Alexe G, Dharia NV, Ross L,
Iniguez AB, Conway AS, Wang EJ, Veschi V, Lam N, Qi J, et al:
CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma
dependency on EZH2. J Clin Invest. 128:446–462. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li Z, Takenobu H, Setyawati AN, Akita N,
Haruta M, Satoh S, Shinno Y, Chikaraishi K, Mukae K, Akter J, et
al: EZH2 regulates neuroblastoma cell differentiation via NTRK1
promoter epigenetic modifications. Oncogene. 37:2714–2727. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bellamy J, Szemes M, Melegh Z, Dallosso A,
Kollareddy M, Catchpoole D and Malik K: Increased efficacy of
histone methyltransferase G9a inhibitors against MYCN-amplified
neuroblastoma. Front Oncol. 10:8182020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tsubota S, Kishida S, Shimamura T, Ohira
M, Yamashita S, Cao D, Kiyonari S, Ushijima T and Kadomatsu K:
PRC2-mediated transcriptomic alterations at the embryonic stage
govern tumorigenesis and clinical outcome in MYCN-driven
neuroblastoma. Cancer Res. 77:5259–5271. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bate-Eya LT, Gierman HJ, Ebus ME, Koster
J, Caron HN, Versteeg R, Dolman M and Molenaar JJ: Enhancer of
zeste homologue 2 plays an important role in neuroblastoma cell
survival independent of its histone methyltransferase activity. Eur
J Cancer. 75:63–72. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhao X, Li D, Huang D, Song H, Mei H, Fang
E, Wang X, Yang F, Zheng L, Huang K and Tong Q: Risk-associated
long noncoding RNA FOXD3-AS1 inhibits neuroblastoma progression by
repressing PARP1-mediated activation of CTCF. Mol Ther. 26:755–773.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li D, Wang X, Mei H, Fang E, Ye L, Song H,
Yang F, Li H, Huang K, Zheng L and Tong Q: Long noncoding RNA
pancEts-1 promotes neuroblastoma progression through
hnRNPK-mediated β-catenin stabilization. Cancer Res. 78:1169–1183.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wu Q, Xiang S, Ma J, Hui P, Wang T, Meng
W, Shi M and Wang Y: Long non-coding RNA CASC15 regulates gastric
cancer cell proliferation, migration and epithelial mesenchymal
transition by targeting CDKN1A and ZEB1. Mol Oncol. 12:799–813.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sanli I, Lalevee S, Cammisa M, Perrin A,
Rage F, Lleres D, Riccio A, Bertrand E and Feil R: Meg3 non-coding
RNA expression controls imprinting by preventing transcriptional
upregulation in cis. Cell Rep. 23:337–348. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang M, Guo C, Wang L, Luo G, Huang C, Li
Y, Liu D, Zeng F, Jiang G and Xiao X: Long noncoding RNA GAS5
promotes bladder cancer cells apoptosis through inhibiting EZH2
transcription. Cell Death Dis. 9:2382018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zheng W and Yu A: EZH2-mediated
suppression of lncRNA-LET promotes cell apoptosis and inhibits the
proliferation of post-burn skin fibroblasts. Int J Mol Med.
41:1949–1957. 2018.PubMed/NCBI
|
|
42
|
Chi R, Chen X, Liu M, Zhang H, Li F, Fan
X, Wang W and Lu H: Role of SNHG7-miR-653-5p-STAT2 feedback loop in
regulating neuroblastoma progression. J Cell Physiol.
234:13403–13412. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chen M, Liu P, Chen Y, Chen Z, Shen M, Liu
X, Li X, Li A, Lin Y, Yang R, et al: Long noncoding RNA FAM201A
mediates the radiosensitivity of esophageal squamous cell cancer by
regulating ATM and mTOR expression via miR-101. Front Genet.
9:6112018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Tripathi V, Ellis JD, Shen Z, Song DY, Pan
Q, Watt AT, Freier SM, Bennett CF, Sharma A, Bubulya PA, et al: The
nuclear-retained noncoding RNA MALAT1 regulates alternative
splicing by modulating SR splicing factor phosphorylation. Mol
Cell. 39:925–938. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Dugimont T, Curgy JJ, Wernert N, Delobelle
A, Raes MB, Joubel A, Stehelin D and Coll J: The H19 gene is
expressed within both epithelial and stromal components of human
invasive adenocarcinomas. Biol Cell. 85:117–124. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kelley RL and Kuroda MI: Noncoding RNA
genes in dosage compensation and imprinting. Cell. 103:9–12. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Koshimizu TA, Fujiwara Y, Sakai N, Shibata
K and Tsuchiya H: Oxytocin stimulates expression of a noncoding RNA
tumor marker in a human neuroblastoma cell line. Life Sci.
86:455–460. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Li Y, Zhuo ZJ, Zhou H, Liu J, Zhang J,
Cheng J, Zhou H, Li S, Li M, He J and Xiao Y: H19 gene
polymorphisms and neuroblastoma susceptibility in Chinese children:
A six-center case-control study. J Cancer. 10:6358–6363. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhang J, Li WY, Yang Y, Yan LZ, Zhang SY,
He J and Wang JX: LncRNA XIST facilitates cell growth, migration
and invasion via modulating H3 histone methylation of DKK1 in
neuroblastoma. Cell Cycle. 18:1882–1892. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wen Y, Gong X, Dong Y and Tang C: Long non
coding RNA SNHG16 facilitates proliferation, migration, invasion
and autophagy of neuroblastoma cells via sponging miR-542-3p and
upregulating ATG5 expression. Onco Targets Ther. 13:263–275. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Russell MR, Penikis A, Oldridge DA,
Alvarez-Dominguez JR, McDaniel L, Diamond M, Padovan O, Raman P, Li
Y, Wei JS, et al: CASC15-S is a tumor suppressor lncRNA at the 6p22
neuroblastoma susceptibility locus. Cancer Res. 75:3155–3166. 2015.
View Article : Google Scholar : PubMed/NCBI
|
